In The Spotlight
DDNews Cancer Research Exclusive
 
 
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
 
(Photo credit: University of Toronto)
 
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
 
 
NEWS
‘Smart bomb’ virus shows promise as a brain tumor immunotherapy, says MD Anderson
 
Syngeneic mouse models are employed extensively in early-stage drug discovery and have become a workhorse for one of the fastest-growing areas of research, immuno-oncology, transforming how investigators approach novel therapies
 
Researchers funded by the National Institutes of Health have completed a detailed genomic analysis, known as the PanCancer Atlas
 
Bellicum reports encouraging results in pediatric patients with primary immunodeficiencies
 
Bavarian Nordic A/S has announced a Phase 2 study to evaluate the combination of CV301, its cancer vaccine, with Bristol-Myers Squibb’s nivolumab in patients with metastatic colorectal cancer
 
A recently completed study supports the value of multiplexed mass spectrometry tests for diagnosing lung cancer and pre-term births
 
Test identifies benign lung nodules with high probability to avoid unnecessary invasive procedures
 
Personal Genome Diagnostics expands its tumor mutational burden patent portfolio
 
  
FEATURES
(Photo credit: NCI, NIH)
 
 
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
 
OPINION
CAR-T Next Generation Immunotherapy: Better Targeting, New Approaches
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

Guest Commentary: Planning successful oncology trials amid a rapidly shifting treatment landscape
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

Enhancing Immuno-Oncology with RNA Interference
by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.